About Azitra
Azitra is a company based in Farmington (United States) founded in 2014. Azitra has raised $37.4 million across 11 funding rounds from investors including HHS, Connecticut Innovations and Bios Partners. The company has 12 employees as of December 31, 2024. Azitra offers products and services including ATR-12, ATR-04, and ATR-01. Azitra operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Farmington, United States
- Employees 12 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Azitra Inc
-
Annual Revenue
$7.5 K (USD)-98.91as on Dec 31, 2024
-
Net Profit
-$8.97 M (USD)20.53as on Dec 31, 2024
-
EBITDA
-$10.09 M (USD)-47.59as on Dec 31, 2024
-
Total Equity Funding
$37.4 M (USD)
in 11 rounds
-
Latest Funding Round
$1 M (USD), Series B
Jan 19, 2021
-
Investors
HHS
& 6 more
-
Employee Count
12
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Azitra
Azitra is a publicly listed company on the AMEX with ticker symbol AZTR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Azitra
Azitra offers a comprehensive portfolio of products and services, including ATR-12, ATR-04, and ATR-01.
Engineered microbe for treating Netherton syndrome via microbial delivery.
Auxotrophic microbe to manage EGFR inhibitor-associated rashes effectively.
Filaggrin protein for addressing ichthyosis vulgaris symptoms.
People of Azitra
Unlock access to complete
Unlock access to complete
Funding Insights of Azitra
Azitra has successfully raised a total of $37.4M across 11 strategic funding rounds. The most recent funding activity was a Series B round of $1 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Azitra
Azitra has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Connecticut Innovations and Bios Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital services for biotech, IT, and innovative sectors in Connecticut.
|
Locked | Locked | Locked | |
|
Venture capital is provided by Bios Partners for biotech innovation.
|
Locked | Locked | Locked | |
|
Venture capital firm investing in life sciences sector
|
Locked | Locked | Locked |
Investor details for Azitra
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Azitra
Investment portfolio details for Azitra
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Azitra
Detailed financials for Azitra
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Azitra Comparisons
Peer comparison for Azitra
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Azitra
Azitra operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Azitra
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Azitra
Complete news archive for Azitra
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Azitra
Azitra was founded in 2014 and raised its 1st funding round 2 years after it was founded.
Azitra is headquartered in Farmington, United States.
Francisco Salva is the current CEO of Azitra.
Azitra is a funded company, having raised a total of $37.4M across 11 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Azitra is 12.
Annual revenue of Azitra is $7.5K as on Dec 31, 2024.
Azitra was founded in 2014 and is headquartered in Farmington, United States, within the biotechnology sector. Focus is placed on microbiome-derived solutions for dermatological disorders, including atopic dermatitis and eczema. The lead candidate, AZT-04, addresses rashes associated with cancer therapies, while preclinical programs encompass AZT-01 for filaggrin delivery in eczema treatment and ATR-12, featuring engineered Staphylococcus epidermidis for LEKTI expression in Netherton syndrome. Operations remain centered on therapeutic development.
Azitra's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Azitra offers ATR-12, ATR-04, and ATR-01.
Yes, Azitra is publicly traded on AMEX under the ticker symbol AZTR.
Azitra has 7 investors. Key investors include HHS, Connecticut Innovations, Bios Partners, Leaps by Bayer, and KdT Ventures.
The ticker symbol of Azitra is AZTR on AMEX.